• Drug Education

    Intravenous Cancer Treatment Education Sheets

    These free intravenous cancer therapy education sheets provide oncology nurses a trusted and reliable resource to use as part of a comprehensive treatment education discussion with patients and caregivers.
  • Drug Education

    Oral Chemotherapy Education Sheets

    These oral chemotherapy patient education sheets are a tool to educate patients and caregivers about oral chemotherapy drugs and their side effects.
  • Drug Education

    Drug Reference Sheets

    The drug reference sheets in ONS Voice are a quick guide to newly approved therapies or drugs with new indications. This resource from ONS clinical staff provides information through a nursing lens and includes the drug’s indication, side-effect profile, nursing considerations, patient education talking points, and more.
  • Drug Education

    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy

    Initially marketed in April 2020 for treatment of adults with metastatic triple negative breast cancer, sacituzumab govitecan-hziy (Trodelvy®) received an additional approval in 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer with prior treatments.
  • Drug Education

    Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl

    Based on LOTIS-2 trial results that reported an overall response rate of nearly 50%, in April 2021 the U.S. Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (ZynlontaTM) for adults with relapsed or refractory large B-cell lymphoma.
  • Drug Education

    Oncology Drug Reference Sheet: Belantamab Mafodotin-Blmf

    A first-of-its-kind antibody-drug conjugate for multiple myeloma, belantamab mafodotin-blmf (Blenrep) received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2020. The approval was based on clinical trial findings that demonstrated a 31% overall response rate that lasted at least six months in 73% of responders.
  • Drug Education

    Oncology Drug Reference Sheet: Panitumumab

    Approved in 2006 as monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) after disease progression following treatment, panitumumab has been a mainstay metastatic disease for more than a decade. In 2014, it received additional indication as first-line therapy for the treatment of patients with EGFR-expressing mCRC in combination with FOLFOX, but in 2017, use was narrowed to wild-type RAS (not mutated RAS). 
  • Drug Education

    Oncology Drug Reference Sheet: Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf Subcutaneous Injection

    Pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injection (PhesgoTM) was approved by the U.S. Food and Drug Administration (FDA) in June 2020 for patients with advanced HER2-positive breast cancer. The drug components are the same as those in FDA-approved IV version, and study results showed comparable safety and efficacy to the IV counterparts. The new administration route allows eligible patients to bypass infusion centers or even receive the therapy at home.

  • Drug Education

    Oncology Drug Reference Sheet: Mosunetuzumab-Axgb

    In an open-label, multicenter, multicohort study that included 90 patients with relapsed or refractory follicular lymphoma who had received at least two prior lines of systemic therapy, 60% of patients receiving treatment with mosunetuzumab-axgb achieved a complete response and 80% had an overall response. On December 22, 2022, the U.S. Food and Drug Administration granted mosunetuzumab-axgb accelerated approval based on those findings.